title: Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
abstract: We studied seventy-five patients with relapsed MM treated with bortezomib-based regimens. DNA was isolated from bone marrow samples at the time of relapse. Global methylation was determined by ELISA, and CpG island DNA methylation profile of 30 genes by a DNA methylation PCR system. Patients with more than 3.95% of total DNA methylated achieved better overall survival (OS) (p=0.004). A relatively low methylation percentage (<1.07%) of NFKB1 was also associated with longer OS after bortezomib treatment (p=0.015). The combination of highly methylated global genome with low NFKB1 methylation status defined a specific subset of patients with better prognosis.
authors: Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, José Carreras Leukaemia Research Institute, University of Barcelona, Barcelona, Spain.
authors: Carlos
authors: C
authors: Fernández de Larrea
authors: Beatriz
authors: B
authors: Martín-Antonio
authors: Maria Teresa
authors: MT
authors: Cibeira
authors: Alfons
authors: A
authors: Navarro
authors: Natalia
authors: N
authors: Tovar
authors: Tania
authors: T
authors: Díaz
authors: Laura
authors: L
authors: Rosiñol
authors: Mariano
authors: M
authors: Monzó
authors: Alvaro
authors: A
authors: Urbano-Ispizua
authors: Joan
authors: J
authors: Bladé
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D019175:DNA Methylation / Q000502:physiology; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D052138:Genes, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D013379:Substrate Specificity
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib